ArticleBMC cancer2011
A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review and meta-analysis comparing the diagnostic capability of automated breast ultrasound and contrast-enhanced ultrasound in breast cancer.Frontiers in oncology · 2023Pooled it
- An exploration of the effects of information giving and information needs of women with newly diagnosed early-stage breast cancer: A mixed-method systematic review.Nursing open · 2022Pooled it
- The Impact of Nurse-Led Intervention on Breast Cancer Screening and Early Detection in China: Randomized Control Trial.Asian Pacific journal of cancer prevention : APJCP · 2025Trial
- Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.Scientific reports · 2018Trial
- Trial
- A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women.British journal of cancer · 2015Trial
- Article
- The relationship between metabolic associated fatty liver disease and thyroid nodule: a cross-sectional study in China.BMC gastroenterology · 2026Observational
- Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the USA: A Multicenter Real-World Study.Annals of surgical oncology · 2026Article
- Retrospective study of hospitalized breast cancer patients in a Zhuhai-based hospital: analysis spanning over 20 years.Frontiers in oncology · 2026Article
- Nutritional status and cancer survival among rural Chinese women: biological mechanisms, health disparities, and translational opportunities.Frontiers in public health · 2026Review
- The circRNA circKNSTRN promotes breast cancer progression by modulating the miR-320a-3p/SPAG5 axis.Scientific reports · 2025Article
- Risk factors of sentinel lymph node metastasis in early-stage invasive breast cancer.Scientific reports · 2025Article
- Article
- Digital humanistic program to manage premature frailty in young breast cancer survivors with gender perspective.NPJ digital medicine · 2025Article
- Cross-sectional study of hepatitis B virus infection in female breast cancer patients in China for the first time diagnosed.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Radiomic analysis of cohort-specific diagnostic errors in reading dense mammograms using artificial intelligence.The British journal of radiology · 2025Article
- The burden and long-term trends of breast cancer by different menopausal status in China.Journal of the National Cancer Center · 2024Article
- Largescale multicenter study of a serum metabolite biomarker panel for the diagnosis of breast cancer.iScience · 2024Article
- Screening of postoperative adjuvant chemotherapy-related serum metabolic markers in breast cancer patients based onTranslational cancer research · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to the very limited cancer registry, incidence and mortality rates for female breast cancer in China are regarded to be increasing especially in the metropolitan areas. Representative data on the breast cancer profile of Chinese women and its time trend over years are relatively rare. The aims of the current study are to illustrate the breast cancer profile of Chinese women in time span and to explore the current treatment approaches to female breast cancer.
methodsThis was a hospital-based nation-wide and multi-center retrospective study of female primary breast cancer cases. China was divided into 7 regions according to the geographic distribution; from each region, one tertiary hospital was selected. With the exception of January and February, one month was randomly selected to represent each year from year 1999 to 2008 at every hospital. All inpatient cases within the selected month were reviewed and related information was collected based on the designed case report form (CRF). The Cancer Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS) was the leading hospital in this study.
resultsFour-thousand two-hundred and eleven cases were randomly selected from the total pool of 45,200 patients and were included in the analysis. The mean age at diagnosis was 48.7 years (s.d. = 10.5 yrs) and breast cancer peaked in age group 40-49 yrs (38.6%). The most common subtype was infiltrating ductal carcinoma (86.5%). Clinical stage I & II accounted for 60.6% of 4,211 patients. Three-thousand five-hundred and thirty-four cases had estrogen receptor (ER) and progestin receptor (PR) tests, among them, 47.9% were positive for both. Two-thousand eight-hundred and forty-nine cases had human epidermal growth factor receptor 2(HER-2) tests, 25.8% of them were HER-2 positive. Among all treatment options, surgery (96.9% (4,078/4,211)) was predominant, followed by chemotherapy (81.4% (3,428/4,211). Much less patients underwent radiotherapy (22.6% (952/4,211)) and endocrine therapy (38.0% (1,599/4,211)).
conclusionsThe younger age of breast cancer onset among Chinese women and more advanced tumor stages pose a great challenge. Adjuvant therapy, especially radiotherapy and endocrine therapy are of great unmet needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.